On March 5, 2021 Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, reported that the Company’s management team will participate in a fireside chat at the Roth Conference being held from March 15-17, 2021 (Press release, Humanigen, MAR 5, 2021, View Source [SID1234576158]). An Advance Video Webinar will also be available starting on Monday, March 8, 2021, not March 5, 2021 as previously communicated.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management will discuss its Phase 3 clinical trial of lenzilumab in patients hospitalized with COVID-19 including the timeline for the topline data release and the submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration, provide an update on the commercial preparation ahead of a potential EUA for lenzilumab and an overview of the Company’s other development programs.

Details for the upcoming webcasts are below:

Roth Conference

Advance Video Webinar viewable starting on Monday, March 8, 2021
Webcast Link: View Source

Live Fireside Chat with Roth Analyst Tony Butler
Date: Tuesday, March 16, 2021
Time: 1:00 PM ET
Time: View Source